ArticleMolecular biology reports2025
A short PIWIL2 isoform PL2L60A induces functional and transcriptional changes indicative of a procancerous phenotype.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRNA-binding PIWIL proteins are known as key contributors to germ cell development and stem cell maintenance, and deregulation of PIWIL expression is associated with various types of cancer. PIWIL2 is usually expressed in the testes, where it acts as a translational regulator and is considered a tumor-barrier protein. In contrast, short PIWIL2 isoforms transcribed from intragenic promoters are associated with testicular tumors called seminomas, suggesting the opposite roles of PIWIL2 and PL2L60A in oncogenesis. The underlying mechanisms are unclear.
methodsTo investigate the effects of the full-length PIWIL2 gene and its short isoform, PL2L60A, we constructed isogenic knock-in (KI) cell lines using CRISPR/Cas9 technology and compared their transcriptional profiles using RNA sequencing. Analysis of KI cell proliferation, migration, and apoptosis was performed using the MTS proliferation assay, wound healing assay, flow cytometry, and caspase activation assay.
resultsPL2L60A-expressing cells had higher proliferative and migratory activities and were less prone to apoptosis than PIWIL2-expressing cells. Transcriptomics analysis of the obtained cell lines by RNA-seq revealed that PL2L60A induced genes involved in angiogenesis, wound healing, cell proliferation, extracellular matrix remodeling, and cancer-promoting signaling; however, the mTORC1-related genes were repressed, which is typical for seminomas.
conclusionOur results indicate that the oncogenic function of PL2L60 is based on the stimulation of molecular pathways typical for seminoma, suggesting PL2L60A as a possible driver of seminoma initiation and/or progression.
Indexed as
Identifiers
41240179What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.